125 related articles for article (PubMed ID: 12778887)
1. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
[No Abstract] [Full Text] [Related]
2. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
Nyvad O; Danielsen H; Madsen S
Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
[No Abstract] [Full Text] [Related]
3. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
4. Benefits of early utilization of intravenous iron.
Vogel S
Nephrol Nurs J; 2000 Feb; 27(1):61-5. PubMed ID: 10852693
[TBL] [Abstract][Full Text] [Related]
5. [Use of venofer for iron deficiency correction in patients undergoing programmed hemodialysis].
Fesiuk AF; Mordik AI; Borisova EV; Borisov AV; Lovchinskiĭ EV
Ter Arkh; 2003; 75(8):59-61. PubMed ID: 14520854
[TBL] [Abstract][Full Text] [Related]
6. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
[TBL] [Abstract][Full Text] [Related]
7. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with intravenous iron and ferritin level].
Fernández-Gallego J; Martín MA; Sujan S; Vega E
Nefrologia; 2010; 30(3):371-2. PubMed ID: 20514109
[No Abstract] [Full Text] [Related]
9. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
[TBL] [Abstract][Full Text] [Related]
10. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
Pizzi LT; Bunz TJ; Coyne DW; Goldfarb DS; Singh AK
Kidney Int; 2008 Dec; 74(12):1588-95. PubMed ID: 19034302
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine for the management of anemia and oxidative stress in hemodialysis patients.
Hsu SP; Chiang CK; Yang SY; Chien CT
Nephron Clin Pract; 2010; 116(3):c207-16. PubMed ID: 20606481
[TBL] [Abstract][Full Text] [Related]
12. [Costs of chronic dialysis in a public hospital: myths and realities].
Lamas J; Alonso M; Saavedra J; García-Trío G; Rionda M; Ameijeiras M
Nefrologia; 2001; 21(3):283-94. PubMed ID: 11471309
[TBL] [Abstract][Full Text] [Related]
13. [Erythropoietin in renal anemia].
Peña Amaro MP; García López J; Camacho Romera M
Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
[No Abstract] [Full Text] [Related]
14. Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
St Peter WL; Obrador GT; Roberts TL; Collins AJ
Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420
[TBL] [Abstract][Full Text] [Related]
15. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP;
Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948
[TBL] [Abstract][Full Text] [Related]
16. [Anemia and renal failure: efficacy of its control].
Fort J
Nefrologia; 2006; 26 Suppl 3():28-32. PubMed ID: 17469424
[No Abstract] [Full Text] [Related]
17. Sodium ferric gluconate and iron requirements in hemodialysis patients.
Navarro JF; Teruel JL
Clin Nephrol; 1997 Sep; 48(3):202. PubMed ID: 9342497
[No Abstract] [Full Text] [Related]
18. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
19. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
Fishbane S; Wagner J
Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
[TBL] [Abstract][Full Text] [Related]
20. Haemoglobin concentrations in chronic kidney disease.
Steinbrook R
Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
